


- [12] For unclear reasons, condensation fails to go to completion, even upon use of a large excess of Grignard reagent, at increased dilution or temperature, or by reverse addition.
- [13] P. S. Bailey, J. E. Keller, *J. Org. Chem.* **1968**, *33*, 2680–2684.
- [14] E. F. J. de Vries, J. Brussee, A. van der Gen, *J. Org. Chem.* **1994**, *59*, 7133–7137.
- [15] D. Kahne, S. Walker, Y. Cheng, D. V. Engen, *J. Am. Chem. Soc.* **1989**, *111*, 6881–6882.
- [16] R. G. Dushin, S. J. Danishefsky, *J. Am. Chem. Soc.* **1992**, *114*, 3471–3475.
- [17] B. A. Garcia, J. L. Poole, D. Y. Gin, *J. Am. Chem. Soc.* **1997**, *119*, 7597–7598.
- [18] R. R. Schmidt, J. Michel, *Angew. Chem.* **1980**, *92*, 763–764; *Angew. Chem. Int. Ed. Engl.* **1980**, *19*, 731–732.
- [19] A. W. Johnson, R. M. Smith, R. D. Guthrie, *J. Chem. Soc. Perkin Trans. 1* **1972**, 2153–2159.
- [20] All new compounds exhibited satisfactory spectral and exact mass data.

Stereocontrolled Synthesis of the Everninomicin A₁B(A)C Ring Framework**

K. C. Nicolaou,* Rosa M. Rodríguez,
Helen J. Mitchell, and Floris L. van Delft


Everninomicin^[1] (13,384-1, **1**), a highly effective antibiotic against drug-resistant bacterial strains, is a member of the



orthosomycin family of compounds. Its novel and challenging structure encompasses, among other structural elements, the nitrosugar **A** and the fully substituted aromatic ring **A₁**, and has stimulated a number of synthetic studies.^[2] Notable

[*] Prof. Dr. K. C. Nicolaou, Dr. R. M. Rodríguez, H. J. Mitchell,
Dr. F. L. van Delft
Department of Chemistry and
The Skaggs Institute for Chemical Biology
The Scripps Research Institute
10550 North Torrey Pines Road, La Jolla, CA 92037 (USA)
Fax: (+1) 619-784-2469
and
Department of Chemistry and Biochemistry
University of California, San Diego
9500 Gilman Drive, La Jolla, CA 92093

[**] This work was financially supported by the National Institutes of Health (USA) and the Skaggs Institute for Chemical Biology. We also thank the M. E. C., Spain (R.M.R., Fullbright), and the Netherlands Organization for Scientific Research (NWO; (F.L.v.D.) for fellowships.



Scheme 1. Synthesis of **8**. a) L-(+)-diisopropyl tartrate (0.09 equiv), Ti(OiPr)₄ (0.072 equiv), *t*BuOOH (2.0 equiv), CH₂Cl₂, –15 °C, 9 d; b) TBSCl (1.2 equiv), imidazole (1.5 equiv), CH₂Cl₂, 0 → 25 °C, 85 % over two steps; c) LiEt₃BH (1.0 M in THF, 1.1 equiv), CH₂Cl₂, –40 °C, 1 h, 91 %; d) CH₂=CHC(O)Cl (1.1 equiv), Et₃N (1.2 equiv), CH₂Cl₂, 0 → 25 °C, 1 h, 90 %; e) (PCy₃)₂Ru(=CHPh)Cl₂ (0.15 equiv), CH₂Cl₂, 40 °C, 72 h, 90 %; f) DIBAL (2.2 equiv), CH₂Cl₂, –78 °C, 1 h, 98 %; g) OsO₄ (0.03 equiv), NMO (1.5 equiv), acetone/H₂O (20/1), 25 °C, 24 h, 97 %; h) Ac₂O (4.0 equiv), Et₃N (6.0 equiv), 4-DMAP (0.1 equiv), CH₂Cl₂, 0 → 25 °C, 2 h, 98 %; i) PhSH (1.3 equiv), Me₃SiOTf (0.03 equiv), CH₂Cl₂, 0 → 25 °C, 3 h, 69 %; j) K₂CO₃ (0.2 equiv), MeOH, 25 °C, 3 h, 100 %. Cy = cyclohexyl, DIBAL = diisobutylaluminum hydride, 4-DMAP = 4-dimethylaminopyridine, NMO = 4-methylmorpholine *N*-oxide, TBS = *tert*-butyldimethylsilyl, Tf = trifluoromethylsulfonyl.

among these are the formation of A₁B(A) and A₁BC systems by Scharf et al.^[2h, k–m] and approaches to 2-deoxy-β-glycosides by Sinay et al.^[2i–j] In the preceding contribution^[3] we described


a stereoselective synthesis of evernitrore (ring **A**) in its activated form (**26**, see Scheme 5). Here we report efficient constructions of rings **B**, **C**, and **A₁** as well as their assembly to the A₁B(A)C ring system (**28**, see Scheme 5) of everninomicin (**1**). The reported chemistry features a number of interesting strategies including a) an approach based on ring-closing olefin metathesis^[4] to the common precursor **8** for carbohydrate systems **B** and **C** (see Scheme 1), b) control of the stereochemistry of the 2-deoxy-β-anomeric by a 1,2-migration and a sulfur-directed glycosidation,^[5] and c) use of an acyl fluoride to effect formation of the sterically demanding ester bond between rings **A₁** and **B**.

An asymmetric synthesis of the common precursor to rings **B** and **C** is shown in Scheme 1. Sharpless epoxidation of prochiral divinylmethanol (**2**)^[6] followed by silylation (TBSCl, imidazole, 85 % over two steps)^[7] furnished epoxide **3**. Regioselective ring opening of **3** with LiEt₃BH (“super hydride”) followed by esterification with acryloyl chloride under basic conditions (Et₃N) provided diolefin **4** (90 %). Ring-closing metathesis induced by (PCy₃)₂Ru(=CHPh)Cl₂ as catalyst afforded lactone **5** (90 %).^[8] Contrary to expectations, dihydroxylation of **5** under a variety of conditions led to the wrong diastereomer, with the oxygen atoms *cis* to the bulky TBS group. Fortunately, reduction of lactone **5** with DIBAL, followed by OsO₄-catalyzed dihydroxylation of the resulting

lactone **5** (90 %).^[8] Contrary to expectations, dihydroxylation of **5** under a variety of conditions led to the wrong diastereomer, with the oxygen atoms *cis* to the bulky TBS group. Fortunately, reduction of lactone **5** with DIBAL, followed by OsO₄-catalyzed dihydroxylation of the resulting

lactol **6** (mixture of anomers), led to the exclusive and quantitative formation of the desired 2,3-diol, which was peracetylated to afford triacetate **7** (98 %, mixture of anomers). Exposure of **7** to PhSH and TMSOTf followed by deacetylation gave dihydroxy- α -thioglycoside **8** as the sole product (69 % over two steps).

Scheme 2 summarizes the selective conversion of thioglycoside **8** into both glycosyl acceptor **12** and glycosyl donor **14**; the 1,2-migration technique previously developed in our




Scheme 2. Synthesis of the **B** and **C** rings. a) 1. $n\text{Bu}_2\text{SnO}$ (1.3 equiv), PhH, 80 °C, 12 h; 2. BnBr (1.5 equiv), $n\text{Bu}_4\text{NI}$ (1.0 equiv), 80 °C, 2 h, 80 %; b) DAST (1.3 equiv), CH_2Cl_2 , 0 °C; c) MeOH (2.0 equiv), SnCl_2 (1.8 equiv), 4-Å molecular sieves, Et_2O , -15 °C, 100 % over two steps, $\alpha/\beta \approx 1:10$; d) $n\text{Bu}_4\text{NF}$ (1.5 equiv), THF, 25 °C, 2 h, 95 %; e) 1. $n\text{Bu}_2\text{SnO}$ (1.3 equiv), PhH, 80 °C, 12 h; 2. PMBCl (1.5 equiv), $n\text{Bu}_4\text{NI}$ (1.0 equiv), 80 °C, 2 h, 92 %; f) DAST (1.3 equiv), CH_2Cl_2 , 0 °C, 100 %. Bn = benzyl, DAST = Et_2NSF_3 , PMB = *p*-methoxybenzyl.


laboratories was employed.^[5] Thus, regioselective protection of position 3 of **8** was effected with $n\text{Bu}_2\text{SnO}$ /BnBr for ring **C** ($\rightarrow$ **9**, 80 %) and with $n\text{Bu}_2\text{SnO}$ /PMBCl for ring **B** ($\rightarrow$ **13**, 92 %). Thioglycosides **9** and **13** underwent smooth 1,2-migration on exposure to DAST to furnish glycosyl fluorides **10** (mixture of β and α anomers, ca. 17:1) and **14** (mixture of β and α anomers, ca. 14:1), respectively, in quantitative yields. As expected, glycosidation of **10** with MeOH and SnCl_2 in Et_2O was directed by the PhS group at C2 to give predominantly the β anomer **11** (91 %, ca. 10:1). Desilylation of **11** gave compound **12** (95 %).

The anticipated difficulties^[2h, k-m] in forming the ester bond between rings **A**₁ and **B** led us to evaluate the use of fluoride **21** (Scheme 3). Its synthesis began with Gatterman formylation of resorcinol **15** ($\rightarrow$ **16**, 92 %). Oxidation of aldehyde **16** to the carboxylic acid (NaClO_2 , 80 %) followed by exposure to benzyl alcohol under Mitsunobu conditions led to the phenol derivative **17** (100 % based on 75 % conversion). Chlorination of **17** (Cl_2 , buffered conditions,^[2e] 70 %) followed by methylation of the phenolic group (CH_2N_2 ,^[2e] 100 %), DIBAL reduction (90 %), and PDC oxidation gave the aldehyde **19** (90 %). Further oxidation of **19** with NaClO_2 and treatment with $[(\text{Me}_2\text{N})_2\text{CF}]\text{PF}_6$ ^[9] then led to the targeted acyl fluoride **21** (97 %), which cleanly withstood chromatographic purification.

The assembly of the **A**₁**BC** ring system **25** from its monocyclic building blocks **12**, **14**, and **21** is shown in Scheme 4. Thus, β -glycosidic coupling,^[5] directed by the PhS



Scheme 3. Synthesis of dichloroisoverninic acyl fluoride (**21**). a) 1. $\text{Zn}(\text{CN})_2$ (1.5 equiv), AlCl_3 (2.4 equiv), HCl (g), 0 °C, 3 h; 2. H_2O , 0 $\rightarrow$ 100 °C, 30 min, 92 %; b) NaClO_2 (2.4 equiv), NaH_2PO_4 (2.5 equiv), DMSO, 0 °C, 12 h, 80 %; c) BnOH (2.0 equiv), DIAD (2.0 equiv), Ph_3P (2.0 equiv), THF, 0 °C, 4 h, 100 % based on 75 % conversion; d) Cl_2 (1.0 M in AcOH, 3.0 equiv), NaOAc (2.25 equiv), AcOH, -50 $\rightarrow$ 0 °C, 70 %; e) CH_2N_2 (excess), Et_2O , dark, 0 °C, 12 h, 100 %; f) DIBAL (1.2 equiv), CH_2Cl_2 , -78 °C, 1 h, 90 %; g) PDC (3.0 equiv), 3-Å molecular sieves, CH_2Cl_2 , 25 °C, 3 h, 90 %; h) NaClO_2 (3.0 equiv), NaH_2PO_4 (3.0 equiv), 2-methyl-2-butene (2.0 M in THF, 4.0 equiv), $t\text{BuOH}$, H_2O , 25 °C, 3 h, 95 %; i) $[(\text{Me}_2\text{N})_2\text{CF}]\text{PF}_6$ (1.5 equiv), $i\text{Pr}_2\text{NEt}$ (2.0 equiv), CH_2Cl_2 , 0 $\rightarrow$ 25 °C, 12 h, 97 %. DIAD = diisopropylazodicarboxylate, PDC = pyridinium dichromate.



Scheme 4. Assembly of the **A**₁**BC** ring system **25**. a) **12** (1.0 equiv), **14** (1.5 equiv), SnCl_2 (1.0 equiv), Et_2O , 4-Å molecular sieves, -15 °C, 12 h, 78 %; b) Raney Ni (excess), MeOH, 65 °C, 2 h; c) BnBr (2.0 equiv), NaH (2.2 equiv), $n\text{Bu}_4\text{NI}$ (0.2 equiv), DMF, 0 °C, 1 h; d) $n\text{Bu}_4\text{NF}$ (1.3 equiv), THF, 25 °C, 2 h, 78 % over three steps; e) 1. **23** (1.0 equiv), 4-Å molecular sieves, THF, 2 h; 2. $n\text{BuLi}$ (1.6 M in hexanes, 2.0 equiv), 25 °C, 1 h; 3. **21** (3.0 equiv), THF, 24 h, 80 %; f) DDQ (2.0 equiv), $\text{CH}_2\text{Cl}_2/\text{H}_2\text{O}$ (15/2), 25 °C, 2 h, 80 %. DDQ = 2,3-dichloro-5,6-dicyano-1,4-benzoquinone.

group at C2, of **12** with **14** was promoted by SnCl_2 in Et_2O to afford disaccharide **22** in 78 % yield. Desulfurization of **22** with Raney Ni, followed by rebenzylation of the partially deprotected hydroxyl group at C3 of ring **C** and desilylation, furnished disaccharide **23** (78 % over three steps). Activation of **23** with $n\text{BuLi}$ facilitated its coupling with fluoride **21** ($\rightarrow$ **24**, 80 %). Finally, selective removal of the PMB group from **24** was achieved with DDQ to furnish **25** (80 %).

The coupling of tricyclic system **25** with glycosyl fluoride **26**^[3] in the presence of $\text{BF}_3 \cdot \text{Et}_2\text{O}$ proceeded stereoselectively to afford the desired α -glycoside **27** (95 %, Scheme 5), from which the benzyl groups were selectively removed by hydrogenolysis to afford the targeted **A**₁**B(A)****C** ring segment **28** of everninomicin (**1**) in 95 % yield.


The described chemistry demonstrates a number of novel synthetic strategies for the asymmetric synthesis of carbohydrate units corresponding to everninomicin and for their

Table 1. Selected physical properties of compounds **22**, **25**, and **28**.

22: R_f = 0.42 (silica gel, 30% Et₂O in hexanes); $[\alpha]_D^{25}$ = -45.3 (c = 0.97 in CHCl₃); IR (thin film): $\tilde{\nu}_{\max}$ = 2930, 2855, 1514, 1472, 1438, 1248, 1102, 1024, 871, 837 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 7.51–7.22 (m, 17H, ArH), 6.79 (d, J = 8.5 Hz, 2H, ArH), 4.92 and 4.72 (AB, J = 10.0 Hz, 2H, CH₂Ar), 4.85 and 4.67 (AB, J = 10.0 Hz, 2H, CH₂Ar), 4.68 (d, J = 9.0 Hz, 1H, H1'), 4.07 (d, J = 8.5 Hz, 1H, H1), 3.77 (s, 3H, *p*-CH₃OAr), 3.56 (dd, J = 9.5, 9.0 Hz, 1H, H4), 3.44 (s, 3H, OCH₃), 3.29 (m, 4H, H3, H3', H4', H5 or H5'), 3.10 (dd, J = 10.5, 8.5 Hz, 1H, H2), 3.05 (dd, J = 9.5, 6.0 Hz, 1H, H5' or H5), 3.00 (dd, J = 11.0, 9.0 Hz, 1H, H2'), 1.45 (d, J = 6.5 Hz, 3H, H6 or H6'), 1.12 (d, J = 6.0 Hz, 3H, H6' or H6), 0.92 (s, 9H, *t*BuSi), 0.06 (s, 3H, CH₃Si), 0.05 (s, 3H, CH₃Si); ¹³C NMR (125 MHz, CDCl₃): δ = 138.8, 136.8, 134.5, 133.0, 130.6, 129.1, 128.5, 127.9, 127.4, 127.1, 126.2, 113.5, 103.9, 102.9, 82.9, 81.7, 80.8, 76.8, 75.7, 75.1, 72.5, 71.1, 57.6, 56.9, 55.6, 55.2, 26.0, 18.7, 18.3, 18.0, -3.4, -3.9; HR-MS (FAB) calcd for C₄₆H₆₀O₈S₂SiC₃ [M + Cs⁺]: 965.2553, found: 965.2521.

25: R_f = 0.29 (silica gel, 60% Et₂O in hexanes); $[\alpha]_D^{25}$ = -6.43 (c = 0.53 in CHCl₃); IR (thin film): $\tilde{\nu}_{\max}$ = 3500, 2925, 1736, 1651, 1558, 1456, 1392, 1258, 1095, 1068, 1034 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 7.60 (bd, J = 8.0 Hz, 2H, ArH), 7.44–7.32 (m, 8H, ArH), 5.03 (s, 2H, A₁-CH₂Ar), 4.82 (dd, J = 9.0, 8.5 Hz, 1H, H4'), 4.80 (bd, J = 9.0 Hz, 1H, H1'), 4.71 and 4.67 (AB, J = 11.5 Hz, 2H, CH₂Ar), 4.34 (dd, J = 10.0, 2.0 Hz, 1H, H1), 3.88 (s, 3H, A₁-OCH₃), 3.79 (bddd, J = 9.5, 9.0, 4.0 Hz, 1H, H3'), 3.59 (ddd, J = 11.5, 8.5, 5.5 Hz, H3), 3.48 (s, 3H, OCH₃), 3.38 (m, 2H, H5 and H5'), 3.29 (dd, J = 9.5, 8.5 Hz, 1H, H4), 2.68 (d, J = 4.0 Hz, 1H, OH), 2.36 (s, 3H, A₁-CH₃), 2.36 (m, 1H, H2'_{eq}), 2.3 (ddd, J = 12.5, 5.5, 2.0 Hz, 1H, H2'_{eq}), 1.74 (ddd, J = 12.5, 9.5, 9.0 Hz, 1H, H2'_{ax}), 1.59 (ddd, J = 12.5, 11.5, 10.0 Hz, 1H, H2'_{ax}), 1.34 (d, J = 5.5 Hz, 1H, H6'), 1.30 (d, J = 6.0 Hz, 1H, H6); ¹³C NMR (125 MHz, CDCl₃): δ = 166.4, 153.0, 151.9, 138.6, 135.9, 133.2, 128.6, 128.5, 127.5, 127.4, 127.0, 125.5, 121.4, 100.5, 100.4, 83.2, 79.9, 77.6, 74.9, 71.8, 70.9, 69.7, 62.4, 56.5, 39.4, 37.0, 30.3, 18.2, 17.7, 17.4; HRMS (FAB) calcd for C₃₆H₄₂O₁₀Cl₂Na [M + Na⁺]: 727.2053, found: 727.2029.

28: R_f = 0.3 (silica gel, 50% Et₂O in hexanes); $[\alpha]_D^{25}$ = -45.2 (c = 0.54 in CHCl₃); IR (thin film): $\tilde{\nu}_{\max}$ = 3456, 2926, 2854, 1725, 1544, 1449, 1389, 1299, 1250, 1127, 1037 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 6.98 (s, 1H, A₁-OH), 4.98 (dd, J = 4.5, 1.5 Hz, 1H, H1''), 4.94 (dd, J = 9.0, 9.0 Hz, 1H, H4'), 4.53 (dd, J = 9.5, 1.5 Hz, 1H, H1'), 4.40 (dd, J = 9.5, 1.5 Hz, 1H, H1), 4.21 (ddd, J = 11.5, 9.5, 5.5 Hz, 1H, H3'), 3.92 (dq, J = 9.0, 6.5 Hz, 1H, H5'), 3.88 (s, 3H, A₁-OCH₃), 3.65 (d, J = 9.0 Hz, 1H, H4''), 3.62 (dq, J = 9.0, 6.5 Hz, 1H, H5''), 3.63 (m, 1H, H3), 3.49 (s, 3H, 1-OCH₃), 3.39 (m, 1H, H5''), 3.35 (s, 3H, 4''-OCH₃), 2.99 (dd, J = 9.0, 8.5 Hz, 1H, H4), 2.47 (dd, J = 14.0, 5.0 Hz, 1H, H2'_{ax}), 2.38 (s, 3H, A₁-CH₃), 2.37–2.28 (m, 2H, H2'_{eq} and H2'_{eq}), 2.03 (dd, J = 14.0, 2.0 Hz, 1H, H2'_{eq}), 1.76–1.58 (m, 2H, H2'_{ax} and H2'_{ax}), 1.67 (s, 3H, 3''-CH₃), 1.44 (d, J = 6.5 Hz, 3H, H6 or H6'), 1.29 (d, J = 6.0 Hz, 3H, H6 or H6'), 0.86 (d, J = 6.0 Hz, 3H, H6''); ¹³C NMR (125 MHz, CDCl₃): δ = 165.5, 153.5, 150.2, 134.7, 125.5, 121.6, 117.6, 100.7, 92.5, 89.9, 89.0, 84.3, 82.8, 75.5, 72.0, 70.2, 69.5, 66.4, 62.1, 60.8, 56.7, 40.0, 38.1, 36.0, 34.3, 29.7, 19.5, 18.1, 17.8, 17.7; HRMS (FAB) calcd for C₃₀H₄₃Cl₂NO₁₄Na [M + Na⁺]: 734.1958, found: 734.1938.



Scheme 5. Construction of the A₁B(A)C ring system. a) **26** (1.8 equiv), BF₃·Et₂O (1.3 equiv), CH₂Cl₂, 4-Å molecular sieves, -30 → 25 °C, 36 h, 95%; b) H₂, Pd/C, *t*BuOMe, 25 °C, 2 h, 95%.

stereocontrolled assembly into a polycyclic framework corresponding to the A₁B(A)C region of the target molecule **1**. The total synthesis of **1** and designed analogues for chemical biology studies should be forthcoming.

Received: February 4, 1998 [Z11436IE]
German version: *Angew. Chem.* **1998**, *110*, 1975–1977

Keywords: everninomicin • carbohydrates • glycosidations • glycosides • metathesis

- [1] a) D. E. Wright, *Tetrahedron* **1979**, *35*, 1207–1237; b) A. K. Ganguly, B. Pramanik, T. C. Chan, O. Sarre, Y.-T. Liu, J. Morton, V. M. Girijavallabhan, *Heterocycles* **1989**, *28*, 83–88; c) A. K. Ganguly in *Topics in Antibiotic Chemistry*, Vol. 2, (Ed.: P. G. Sammes), Wiley, New York, **1978**, pp. 61–96; d) A. K. Ganguly, V. M. Girijavallabhan, O. Sarre, (Schering-Plough), WO-A 87/02366, **1987** [*Chem. Abstr.* **1987**, *107*, 97061]; e) P. Mahesh, V. P. Gullo, H. Roberta, D. Loebenberg, J. B. Morton, G. H. Miller, H. Y. Kwon, (Schering-Plough), EP-B 0 538 011 A1, **1992** [*Chem. Abstr.* **1993**, *119*, 10331].
- [2] a) J. Brimacombe, L. W. Doner, *J. Chem. Soc. Perkin Trans. 1* **1974**, 63–65; b) J. Yoshimura, M. Matzuzama, M. Funabashi, *Bull. Chem. Soc. Jpn.* **1978**, *51*, 2064–2067; c) J. Brimacombe, A. S. Mengech, *J. Chem. Soc. Perkin Trans. 1* **1980**, 2055–2059; d) I. Lundt, J. Thiem, A. Prahst, *J. Org. Chem.* **1984**, *49*, 3063–3069; e) J. Dorhagen, H.-D. Scharf, *Tetrahedron* **1985**, *41*, 173–175; f) J. Thiem, A. Prahst, I. Lundt, *Liebigs Ann. Chem.* **1986**, 1044–1056; g) S. Hatateyama, K. Sakurai, S. Tanano, *Tetrahedron Lett.* **1986**, *27*, 4485–4488; h) P. Jütten, J. Dorhagen, H.-D. Scharf, *Tetrahedron* **1987**, *43*, 4133–4140; i) M. Truntel, P. Tavecchia, A. Veyrieres, P. Sinay, *Carbohydr. Res.* **1989**, *191*, 29–52; j) P. Tavecchia, M. Truntel, A. Veyrieres, P. Sinay, *Tetrahedron Lett.* **1989**, *30*, 2533–2536; k) P. Jütten, H.-D. Scharf, *Carbohydr. Res.* **1991**, *212*, 93–108; l) P. Jütten, H.-D. Scharf, G. Raabe, *J. Org. Chem.* **1991**, *56*, 7144–7149; m) C. Zagar, H.-D. Scharf, *Carbohydr. Res.* **1993**, *248*, 107–118.
- [3] K. C. Nicolaou, H. J. Mitchell, F. L. van Delft, F. Rübsam, R. M. Rodríguez, *Angew. Chem.* **1998**, *110*, 1972–1974; *Angew. Chem. Int. Ed.* **1998**, *37*, 1871–1874.
- [4] Recent review: M. Schuster, S. Blechert, *Angew. Chem.* **1997**, *109*, 2124–2145; *Angew. Chem. Int. Ed. Engl.* **1997**, *36*, 2036–2056.
- [5] a) K. C. Nicolaou, T. Ladduwahetty, J. L. Randall, A. Chucholowski, *J. Am. Chem. Soc.* **1986**, *108*, 2466–2467; b) K. C. Nicolaou, C. W. Hummel, N. J. Bockovich, C.-H. Wong, *J. Chem. Soc. Chem. Commun.* **1991**, 870–872.
- [6] D. B. Smith, Z. Wang, S. L. Schreiber, *Tetrahedron* **1990**, *46*, 4793–4808.
- [7] A higher yield was obtained by modification of the workup (high dilution with hexane, washing with H₂O) of the reported silylation procedure: J. Jin, S. M. Weinreb, *J. Am. Chem. Soc.* **1997**, *119*, 5773–5775.
- [8] For a recent example of a synthesis of lactams based on olefin metathesis, see F. P. J. T. Rutjes, *Tetrahedron Lett.* **1997**, *38*, 677–680.
- [9] L. A. Carpino, A. El-Faham, *J. Am. Chem. Soc.* **1995**, *117*, 5401–5402.